Cargando…

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?

Background: Combined immunotherapy has significantly improved survival of patients with advanced melanoma, but there are still patients that do not benefit from it. Early biomarkers that indicate potential resistance would be highly relevant for these patients. Methods: We comprehensively analyzed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amaral, Teresa, Schulze, Martin, Sinnberg, Tobias, Nieser, Maike, Martus, Peter, Battke, Florian, Garbe, Claus, Biskup, Saskia, Forschner, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281129/ https://www.ncbi.nlm.nih.gov/pubmed/32354124 http://dx.doi.org/10.3390/cancers12051101

Ejemplares similares

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study
por: Forschner, Andrea, et al.
Publicado: (2020)

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
por: Forschner, Andrea, et al.
Publicado: (2019)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy
por: Schmitt, Marisa, et al.
Publicado: (2021)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
por: Hilke, Franz J., et al.
Publicado: (2020)

Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
por: Meraz-Torres, Francisco, et al.
Publicado: (2020)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
por: Serna-Higuita, Lina María, et al.
Publicado: (2021)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

The question of WGS’s clinical utility remains unanswered
por: Battke, Florian, et al.
Publicado: (2021)

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
por: Kosnopfel, Corinna, et al.
Publicado: (2017)

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
por: Amaral, Teresa, et al.
Publicado: (2020)

Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study
por: Wiens, Lisa, et al.
Publicado: (2021)

Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2014)

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
por: Reiter, Selina, et al.
Publicado: (2023)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
por: Sinnberg, Tobias, et al.
Publicado: (2018)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition
por: Schmitt, Marisa, et al.
Publicado: (2021)

Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition
por: Makino, Elena, et al.
Publicado: (2020)

β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance
por: Sinnberg, Tobias, et al.
Publicado: (2011)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype
por: Sinnberg, Tobias, et al.
Publicado: (2018)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

The need for psycho-oncological support for melanoma patients: Central role of patients’ self-evaluation
por: Mayer, Simone, et al.
Publicado: (2017)

Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion
por: Kosnopfel, Corinna, et al.
Publicado: (2020)

Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series
por: Walter, Christina, et al.
Publicado: (2020)

Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report
por: Blumendeller, Carolin, et al.
Publicado: (2021)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines
por: Sinnberg, Tobias, et al.
Publicado: (2014)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis
por: Weide, Benjamin, et al.
Publicado: (2013)

Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
por: Hickmann, Anne-Katrin, et al.
Publicado: (2019)

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
por: Weide, Benjamin, et al.
Publicado: (2013)

Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study
por: Tropitzsch, Anke, et al.
Publicado: (2021)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9bnkpimn4lktn9k8d98ois1504